The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Multiple Myeloma Staging (Detailed)

Plasma cell neoplasm staging using Revised International Staging System (R-ISS) integrating beta-2 microglobulin, albumin, LDH, and high-risk cytogenetics (del(17p), t(4;14), t(14;16)), complemented by Mayo Stratification (mSMART) and R2-ISS to guide induction therapy intensity, transplant eligibility, and prognosis prediction.

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Hematoloji department. Book Appointment →

What is Multiple Myeloma Staging (Detailed)?

Multiple myeloma is a plasma cell neoplasm characterized by clonal proliferation of malignant plasma cells in bone marrow producing monoclonal immunoglobulin (M-protein) detected in serum and/or urine, causing CRAB criteria (hyperCalcemia, Renal failure, Anemia, Bone lesions). Staging systems have evolved from Durie-Salmon (1975, based on M-protein levels and bone lesions) to International Staging System (ISS, 2005, using albumin and beta-2 microglobulin), to Revised ISS (R-ISS, 2015, adding LDH and high-risk cytogenetics by FISH).

R-ISS Stage I: ISS Stage I (beta-2 microglobulin <3.5 mg/L AND albumin >=3.5 g/dL) AND standard-risk cytogenetics AND normal LDH (5-year survival ~82%). R-ISS Stage II: not Stage I or III (5-year survival ~62%). R-ISS Stage III: ISS Stage III (beta-2 microglobulin >=5.5 mg/L) AND high-risk cytogenetics (del(17p), t(4;14), t(14;16)) OR elevated LDH (5-year survival ~40%). Newer R2-ISS adds gain/amplification 1q21 as additional risk factor and uses 4-tier system (I, II, III, IV) with improved prognostic discrimination. Mayo Stratification (mSMART) classifies as standard-risk (trisomies, t(11;14), t(6;14)) versus high-risk (t(4;14), t(14;16), t(14;20), del(17p), p53 deletion/mutation, gain 1q, R-ISS III).

Modern staging incorporates minimal residual disease (MRD) assessment by next-generation sequencing (sensitivity 10^-6) or multiparameter flow cytometry (sensitivity 10^-5), with MRD-negativity strongly correlating with progression-free and overall survival. Imaging staging uses whole-body low-dose CT, PET/CT, or whole-body MRI to detect focal lesions and define disease distribution per IMWG criteria. Treatment is risk-adapted: standard-risk transplant-eligible patients receive 4-6 cycles of quadruplet induction (Dara-VRd: daratumumab, bortezomib, lenalidomide, dexamethasone) followed by autologous stem cell transplantation and lenalidomide maintenance; high-risk patients receive intensified induction with consideration of tandem transplantation; transplant-ineligible patients receive Dara-Rd or Dara-VRd-Lite. Newer therapies include CAR T-cell therapies (idecabtagene vicleucel, ciltacabtagene autoleucel targeting BCMA), bispecific antibodies (teclistamab, elranatamab targeting BCMA/CD3; talquetamab targeting GPRC5D).

Symptoms

Bone pain, especially back and ribs
Pathologic fractures from lytic lesions
Fatigue and weakness from anemia
Recurrent infections from immunoparesis
Hypercalcemia symptoms (confusion, constipation, polyuria)
Renal insufficiency and proteinuria
Hyperviscosity symptoms (headache, blurred vision, bleeding)
Spinal cord compression from vertebral lesion
Peripheral neuropathy (light chain amyloidosis or treatment-related)

Risk Factors

Age over 65 years (median diagnosis age 69)
Male sex (slightly higher incidence)
African ancestry (twice the incidence)
Family history of multiple myeloma
Monoclonal gammopathy of undetermined significance (MGUS) progression risk 1% per year
Smoldering multiple myeloma progression
Obesity
Ionizing radiation exposure
Pesticide and benzene exposure

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Persistent bone pain, especially back
  • Pathologic fracture without significant trauma
  • Unexplained anemia in older adults
  • Recurrent infections in elderly
  • Hypercalcemia of unknown cause
  • Renal failure with proteinuria
  • Elevated total protein with abnormal serum protein electrophoresis
  • Spinal cord compression symptoms
  • Known MGUS or smoldering myeloma needing surveillance

Treatment Methods

01
Diagnostic workup: SPEP, IFE, serum free light chain assay, 24-hour urine, bone marrow biopsy
02
Cytogenetic FISH for del(17p), t(4;14), t(14;16), gain 1q21
03
Imaging: whole-body low-dose CT, PET/CT, or whole-body MRI
04
Risk stratification with R-ISS, R2-ISS, mSMART
05
Quadruplet induction: Dara-VRd (daratumumab + bortezomib + lenalidomide + dexamethasone)
06
Autologous stem cell transplantation in eligible patients
07
Lenalidomide maintenance until progression
08
Bispecific antibodies (teclistamab, elranatamab, talquetamab) for relapsed/refractory
09
CAR T-cell therapy (idecabtagene, ciltacabtagene) for triple-class refractory
10
MRD assessment by NGS or multiparameter flow cytometry
11
Bisphosphonates (zoledronic acid) or denosumab for skeletal-related events

Which Department to Visit?

You can visit our Hematoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Hematoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.